{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.31","upperLimit":"3.58","value":"3.29"},{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"1.41","upperLimit":"NA","value":"2.50"},{"groupId":"OG002","lowerLimit":"1.41","upperLimit":"5.26","value":"3.32"},{"groupId":"OG003","lowerLimit":"1.7","upperLimit":"5.6","value":"3.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"105"}],"units":"Participants"}],"description":"PFS is the time from the date of first dosing until the date of objective disease progression or death (by any cause) regardless of whether the participant discontinues the study treatments. Progression is identified based on CT and/or PET scans evaluated by investigator per Lugano criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group A: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG000","title":"AZD4205 Group A"},{"description":"Group B: Open label AZD4205 at 250 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG001","title":"AZD4205 Group B"},{"description":"Group C: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG002","title":"AZD4205 Group C"},{"description":"Group D: Open label AZD4205 at 150 mg (RP2D), once daily (Phase 2)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG003","title":"AZD4205 Group D"}],"paramType":"MEDIAN","populationDescription":"Part A: Safety Analysis Set Part B: Evaluable for Survival Set","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Part A and Part B: PFS Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"months"}